Showing results (1-10 of 82) with videos related to
Sort By:
Pageof 9
Translational Oncology|May 16, 2021
The other side of the coin: dissecting molecular mechanisms behind hereditary breast cancer in search of therapeutic opportunitiesStefania Stella, Federica Martorana, Livia Manzella, et al.Future Oncology (London, England)|December 8, 2015
Biomarkers and prognostic factors for malignant pleural mesotheliomaPaolo Vigneri, Federica Martorana, Livia Manzella, et al.Journal of Medicinal Food|March 24, 2012
Double-face activity of resveratrol in voluntary runners: assessment of DNA damage by comet assayBarbara Tomasello, Salvatore Grasso, Giuseppe Malfa, et al.Clinical and Experimental Rheumatology|July 8, 2016
Thrombin generation assay: interactions between chronic inflammation and haemostasis in patients with autoimmune diseasesLaura Solfietti, Giovanni B Binello, Stefania Stella, et al.Oncotargets and Therapy|April 14, 2023
Potential Therapeutic Targets for Luminal Androgen Receptor Breast Cancer: What We Know so FarStefania Stella, Federica Martorana, Michele Massimino, et al.Photochemical & Photobiological Sciences : Official Journal of the European Photochemistry Association and the European Society for Photobiology|March 2, 2005
Rufloxacin induced photosensitization in bio-models of increasing complexityAlfio Catalfo, Christian Scifo, Stefania Stella, et al.British Journal of Haematology|November 21, 2007
Age-dependent accumulation of monoclonal CD4+CD8+ double positive T lymphocytes in the peripheral blood of the elderlyPaolo Ghia, Giuseppina Prato, Stefania Stella, et al.Expert Review of Anticancer Therapy|February 9, 2016
Imatinib mesylate in chronic myeloid leukemia: frontline treatment and long-term outcomesFabio Stagno, Stefania Stella, Antonio Spitaleri, et al.Genes|July 29, 2023
Single-Cell Analysis in the Omics Era: Technologies and Applications in CancerMichele Massimino, Federica Martorana, Stefania Stella, et al.Cancer Diagnosis & Prognosis|April 11, 2022
A Treatment-free Interval Allowed by Ponatinib as Fourth-line TherapyAnna Bulla, Uros Markovic, Claudia Bellofiore, et al.Pageof 9